The increasing occurrence of highly potent or frequent-administration therapies in the drug development pipeline means that the low solubility of drugs is becoming a potential bottleneck for pharmaceutical formulators. This not only makes…

Create a future without cancer. The time to act is now. World Cancer Day takes place every year on 4 February and will be held for the 24rd time in 2024 under the theme "Close the Care Gap". The day was initiated as a global…

Ischemic stroke accounts for about 87% of all strokes, causing long-term disability in adults, and is the second leading cause of death worldwide. In search of new therapeutic modalities, the use of neuroprotective agents loaded in…

The FDA approved 50 novel drugs in 2021, including the first KRAS inhibitor for cancer and the first anti-amyloid antibody for Alzheimer’s disease. Article by Asher Mullard - Nature Reviews Drug Discovery - 04 January 2022 The FDA’s…

Self-microemulsifying drug delivery systems (SMEDDSs) have recently returned to the limelight of academia and industry due to their enormous potential in oral delivery of biomacromolecules. However, information on gastrointestinal lipolysis…

Ibrutinib (IBR) is the choice of drug for the treatment of chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). IBR has low oral bioavailability of 2.9% owing to its high first pass metabolism. Present study was aimed to…

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the…

03. March 2018 Pharma Deals, Investments and M&As in January 2018 Big bang M&As: Sanofi acquires Bioverativ, Ablynx; Celgene acquires Juno Therapeutics The year…

04. January 2018 The year gone by saw the highest number of generic drug approvals by the US Food and Drug Administration (FDA), along with the most ever novel drugs (46); the most ever novel devices, and the…